SATURDAY, SEPTEMBER 24, 2016

Novavax

20 Firstfield Road
Gaithersburg, MD - 20878

Novavax News

Novavax releases data from Phase 2 of maternal vaccination clinical trial

Clinical-stage vaccine company Novavax Inc. last week released positive results from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate. Read More »

Novavax RSV F vaccine trial for women shows promise

Clinical trial subjects show improved immune system response after receiving vaccine. Read More »

Novavax's RSV vaccine for seniors shows promise in Phase Two trials

F-protein vaccine is the first attempt to vaccinate for RSV that has shown effectiveness in any population. Read More »

Novavax names vice president of finance

Novavax, Inc., a clinical-stage vaccine company that specializes in the development, discovery and commercialization of recombinant nanoparticle vaccines and adjuvants, named Chris Dunne as its new vice president of finance Read More »

Novavax releases positive results of phase 2 RSV F-protein vaccine clinical trial

Novavax recently announced the positive top-line data from the company’s phase 2 clinical trial of its respiratory syncytial virus (RSV) F-protein vaccine, which is specifically designed for older adults. Read More »

Novavax unveils positive results for seasonal flu vaccine

Novavax Inc., a clinical-stage vaccine company that specializes in the discovery, creation and sales of recombinant nanoparticle vaccines and adjuvants, recently announced the positive results from its phase two trial of the company’s quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate. Read More »

Boudreaux joins Novavax Board of Directors

Novavax Inc., a clinical-stage vaccine company that specializes on discovering, creating and commercializing recombinant nanoparticle vaccines and adjuvants, recently announced that it has chosen added Gail Boudreaux to the company’s board of directors. Read More »

Novavax names Brian Rosen VP of Government Affairs

Brian Rosen will lead vaccine company's policy and government affairs efforts. Read More »

Novavax begins Ebola vaccine Phase 1 clinical trial

Novavax, Inc. recently announced that it is beginning its phase 1 clinical trial of its Ebola vaccine. Read More »

Novavax clinical trial to evaluate new flu vaccine

Novavax, Inc., has announced that patient enrollment has begun in its Phase 2 clinical trial of its new recombinant quadrivalent seasonal influenza virus-like particle vaccine, entitled Seasonal Influenza VLP. Read More »

Novavax testing RSV vaccine on children

Novavax Inc. announced on Monday that it has begun enrolling pediatric participants in a Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine). Read More »

Novavax’s H7N9 vaccine fast-tracked by U.S. FDA

The latest avian influenza vaccine, developed by Novavax, is being fast-tracked by the US Food and Drug Administration (FDA). Read More »

Pregnant women may benefit from RSV vaccine

Results of a study shared at the 8th Vaccine & ISV Congress in Philadelphia on Sunday showed that pregnant women may benefit from Novavax Inc.'s RSV F-Protein Nanoparticle vaccine Read More »